PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript

Kylie O’Keefe: Yeah. Absolutely. So on the Emflaza front, Tazeen, I think what we continue to do Emflaza as the standard-of-care across all DMD patients. And we have been able to demonstrate the benefit of Emflaza in a number of different milestones and we continue to believe that that’s not going to shift in the near-term. I think from a loss of exclusivity perspective, we have a number of strategies that we’re looking at to be able to preserve the business, and again, that doesn’t shift based on the Vamorolone approval. We have good, strong relationships across our customer base and with patient advocacy groups and we will continue to leverage those relationships as we move forward. On the milestone question…

Tazeen Ahmad: Are you able to provide any color on the specific strategies that you’re going to use for Emflaza?

Kylie O’Keefe: Yeah. Absolutely. So there’s four main pillars that we’re focused on with regards to protecting the business. So one is ensuring that we have an enhanced patient support program, which is really, really important for particularly DMD patients those in Medicaid as an example, and then also partnering with specialty pharmacies, partnering with payers, and partnering with manufacturers to be able to ensure that, we’re doing the best for the patients and protecting the business. So there are some of the key strategies that we’re looking at, as well as a dispenses written program that the team is working on as we speak.

Tazeen Ahmad: Okay. Thank you.

Operator: Thank you.

Kylie O’Keefe: And then in your — just to answer the last question, Tazeen, around the milestones for Censa. So you are correct. We obviously had paid the $30 million in equity in 2023. Don’t expect any additional milestones for Censa in 2023, but we had shared in the Q that we expect $65 million worth of regulatory success based milestone for Censa in the next 12 months, so in 2024, and we haven’t broken out the specifics around that.

Operator: I’m showing no further questions at this time. Let’s turn the call back over to Dr. Matthew Klein, Chief Executive Officer, for any closing remarks.

End of Q&A:

Matthew Klein: Great. Thank you. Thank you all for joining the call today. We look forward to a strong closeout in 2023 as we get ready for what’s clearly also going to be a busy 2024. And we’ll look forward to sharing updates with you as they become available. Thank you all again and have a good evening.

Operator: Thank you. Ladies and gentlemen, this does conclude today’s conference. Thank you all for participating. You may now disconnect. Have a great day.